Isogenica Announces Renewal of Licence Agreement by Harpoon Therapeutics

CAMBRIDGE, England–(BUSINESS WIRE)–#biotech–Isogenica Ltd, a leader in the design and construction of innovative and
highly diverse synthetic antibody libraries, today announced that
Harpoon Therapeutics, a preclinical stage biotechnology company
specialising in the development of multiple T-cell recruiting platforms
for the treatment of cancer and other immunologic disorders, is renewing
the licence and option agreement originally signed with Isogenica in
June 2016.

Under the terms of the original agreement, Isogenica has granted Harpoon
licences to its family of llamdA™ VHH single-domain antibody libraries
for the discovery, development and commercialisation of therapeutic
products derived from these libraries. Isogenica is entitled to an
upfront and annual licence payments. If antibodies are advanced into
development, Isogenica is entitled to further commercial upfront
payments, licence fees and milestones payments.

Adam Collier, Isogenica’s Director of Commercial Development commented:
“We are delighted that Harpoon, one of our earliest VHH library
licensees, has made the decision to renew this licence and option
agreement. Isogenica sees this as further validation of the library in a
truly operational setting. With our unique synthetic antibody libraries
and leading biopharmaceutical discovery technologies, Isogenica is
uniquely positioned to create significant value and opportunities for
our partners”.

Isogenica is a synthetic biology company focusing on the design and
build of diverse antibody libraries for use in biopharmaceuticals.
Partners can access an advanced camelid single-domain antibody library
(llamdA™) and state-of-the-art, fully synthetic and highly diverse human
antibody libraries. The company uses its proprietary Colibra™ library
technology to ensure that the constructs very accurately reflect its
advanced library designs. Libraries can be screened in various formats,
including phage and CIS-Display, a proprietary in vitro display
technology which maintains the high diversity of the llamdA™ libraries
through the discovery process.

Harpoon is a preclinical stage biotechnology company founded by MPM
Capital to develop multiple T-cell recruiting platforms leading to
therapies for cancer patients and other immunologic disorders. Harpoon
created its proprietary TriTAC™ biologics platform to harness T cells to
kill tumor and other cell types by recruiting T cells and other immune
cells. This approach has been optimised to penetrate tissues and extend
serum exposure, and has the potential to address a broad range of
cancers and immunologic diseases.


Notes to Editors

About Isogenica

Isogenica licenses advanced synthetic antibody libraries and display
technologies to enable its partners’ antibodies discovery activities.
These libraries are available for license and screening partnerships,
which together with its expertise in the screening of displayed peptide
and scaffold libraries, can facilitate client’s biologics discovery


Adam Collier, Director of Commercial Development
01223 533 680
Sarah Brereton, Director
T: 01223 813 560